<DOC>
	<DOCNO>NCT00054171</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill cancer cell . Photosensitizing drug aminolevulinic acid absorb cancer cell , expose light , become active kill cancer cell . PURPOSE : Randomized phase II trial study effectiveness photodynamic therapy use aminolevulinic acid treat patient cutaneous T-cell lymphoma , B-cell lymphoma , early chronic lymphocytic leukemia involve skin .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine pain grade epidermal toxic response ( ETR ) patient T-cell B-cell lymphoma early chronic lymphocytic leukemia cutaneous infiltrates treat photodynamic therapy use aminolevulinic acid . - Determine feasibility maintain pain grade 1 less approximate ETR 2 patient receive 12 session regimen . - Determine maximal irradiance corresponding exposure among multiple treatment site among different site different patient . - Determine cumulative response achieve completion treatment patient . - Determine number session require complete treatment patient . - Correlate ETR incremental treatment response patient treat regimen . OUTLINE : This randomize study . Patients ' individual lesion randomize 1 3 treatment arm . - Arm I : Patients receive short duration topical aminolevulinic acid ( ALA ) lesion surround normal skin . The lesion illuminate red light 30 minute . - Arm II : Patients receive medium duration ALA follow light illumination arm I . - Arm III : Patients receive long duration ALA follow light illumination arm I . In arm , treatment repeat every 2 week 12 course absence unacceptable toxicity progressive ( systemic ) disease . Additional patient accrue treatment arm least 2 3 patient arm experience 25 % cumulative clinical response . Patients follow 1 , 3 , 6 month every 6 month 2 year . PROJECTED ACCRUAL : A total 4-10 patient accrue study within 5-7 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm diagnosis : Cutaneous Bcell Tcell lymphoma confine skin No evidence internal disease peripheral adenopathy Early chronic lymphocytic leukemia cutaneous Bcell infiltrate require systemic therapy Stable slowly progressive disease expect substantially change treatment PATIENT CHARACTERISTICS : Age Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing No porphyria know hypersensitivity porphyrins No known photosensitivity diseases PRIOR CONCURRENT THERAPY : Biologic therapy Concurrent clinically necessary interferon alfa allow Chemotherapy No concurrent systemic multiagent chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent local radiotherapy study lesions No concurrent whole body radiotherapy Surgery Not specify Other More 1 month since prior topical therapy study lesion Concurrent topical therapy nonstudy lesion allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
</DOC>